{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:33Z","timestamp":1791067053741,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ebr.2025.100746","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:25:06Z","timestamp":1738427106000},"page":"100746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Antiseizure medications and their differing effects on cardiovascular risk"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1593-1736","authenticated-orcid":false,"given":"Aleena","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassil","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"LoPinto-Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2025.100746_b0005","doi-asserted-by":"crossref","unstructured":"LoPinto-Khoury C. Long term effects of antiseizure medications. Seminars in Neurology Vol. 42. No. 05. 2022.","DOI":"10.1055\/a-1958-0802"},{"key":"10.1016\/j.ebr.2025.100746_b0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"LoPinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.ebr.2025.100746_b0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF02533749","article-title":"Inhibition of cholesterol synthesis by oxygenated sterols","volume":"13","author":"Kandutsch","year":"1978","journal-title":"Lipids"},{"key":"10.1016\/j.ebr.2025.100746_b0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eplepsyres.2015.03.002","article-title":"Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review","volume":"113","author":"Vyas","year":"2015","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.17712\/nsj.2017.2.20160342","article-title":"Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment","volume":"22","author":"Zuberi","year":"2017","journal-title":"Neurosciences (Riyadh)"},{"issue":"4","key":"10.1016\/j.ebr.2025.100746_b0030","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.21615","article-title":"Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein","volume":"65","author":"Mintzer","year":"2009","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.ebr.2025.100746_b0035","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/epi.14554","article-title":"Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly","volume":"59","author":"Mintzer","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ebr.2025.100746_b0040","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.eplepsyres.2014.04.006","article-title":"Vascular function and risk factors in children with epilepsy: associations with sodium valproate and carbamazepine","volume":"108","author":"Keenan","year":"2014","journal-title":"Epilepsy Res"},{"issue":"9","key":"10.1016\/j.ebr.2025.100746_b0045","first-page":"913","article-title":"Effect of carbamazepine on serum lipids and liver function tests","volume":"42","author":"Aggarwal","year":"2005","journal-title":"Indian Pediatr"},{"issue":"11","key":"10.1016\/j.ebr.2025.100746_b0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/0883073808318538","article-title":"Lipid profile, apolipoproteins A and B in children with epilepsy","volume":"23","author":"Tomoum","year":"2008","journal-title":"J Child Neurol"},{"issue":"7","key":"10.1016\/j.ebr.2025.100746_b0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s004310050664","article-title":"Serum lipids in epileptic children treated with carbamazepine and valproate","volume":"156","author":"S\u00f6z\u00fcer","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ebr.2025.100746_b0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.seizure.2017.03.007","article-title":"Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study","volume":"48","author":"Sidhu","year":"2017","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.ebr.2025.100746_b0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0883073814551388","article-title":"Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study","volume":"30","author":"El-Farahaty","year":"2015","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.ebr.2025.100746_b0070","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/biomedicines11092444","article-title":"C-reactive protein: the quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine","volume":"11","author":"Amezcua-Castillo","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ebr.2025.100746_b0075","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/jalm\/jfac069","article-title":"Comparison of High-Sensitivity C-Reactive Protein vs C-reactive Protein for Cardiovascular Risk Prediction in Chronic Cardiac Disease","volume":"7","author":"Han","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.ebr.2025.100746_b0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.ebr.2025.100746_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.eplepsyres.2013.08.011","article-title":"Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: a cross sectional study","volume":"107","author":"Sankhyan","year":"2013","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.ebr.2025.100746_b0090","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.amjcard.2006.06.032","article-title":"Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease","volume":"98","author":"Liu","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ebr.2025.100746_b0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.08.027","article-title":"Influence of antiepileptic drugs on serum lipid levels in adult epilepsy patients","volume":"127","author":"Yamamoto","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100746_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2016.05.023","article-title":"Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: a small phase IIIb, prospective, multicenter, open-label trial","volume":"62","author":"Elger","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.ebr.2025.100746_b0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12944-023-01993-y","article-title":"Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets","volume":"23","author":"Chen","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1515\/JPEM.2003.16.2.193","article-title":"Effect of long-term carbamazepine therapy on serum lipids, vitamin B12 and folic acid levels in children","volume":"16","author":"Deda","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ebr.2025.100746_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(00)00119-4","article-title":"The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy","volume":"41","author":"Eir\u00eds","year":"2000","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.ebr.2025.100746_b0120","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.12669\/pjms.335.12982","article-title":"Correlation between hyperhomocysteinemia and common carotid artery intima media thickness in carbamazepine treated epileptic patients using ultrasonography","volume":"33","author":"Bano","year":"2017","journal-title":"Pak J Med Sci"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1528-1167.2009.02303.x","article-title":"Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs","volume":"51","author":"Belcastro","year":"2010","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.seizure.2005.11.002","article-title":"Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6","volume":"15","author":"Sener","year":"2006","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.ebr.2025.100746_b0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/labmed-2016-0059","article-title":"Methylenetetrahydrofolate reductase gene polymorphism and clinical importance in epilepsy patients using valproic acid, carbamazepine and levetiracetam","volume":"41","author":"Aydin","year":"2017","journal-title":"Laboratoriums Medizin"},{"issue":"3","key":"10.1016\/j.ebr.2025.100746_b0140","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.pnpbp.2007.12.018","article-title":"Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy","volume":"32","author":"Vurucu","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3988\/jcn.2019.15.2.149","article-title":"Short-term and long-term effects of levetiracetam monotherapy on homocysteine metabolism in children with epilepsy: a prospective study","volume":"15","author":"Attilakos","year":"2019","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.ebr.2025.100746_b0150","article-title":"Meta-analysis of plasma homocysteine levels in valproic acid treated patients with epilepsy","volume":"14","author":"Ni","year":"2014","journal-title":"Chin. J. Contempor. Neurol. Neurosurg."},{"issue":"3","key":"10.1016\/j.ebr.2025.100746_b0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2012.04.132","article-title":"B-vitamin deficiency in patients treated with antiepileptic drugs","volume":"24","author":"Mintzer","year":"2012","journal-title":"Epilepsy Behavior"},{"issue":"4","key":"10.1016\/j.ebr.2025.100746_b0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000208","article-title":"Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings","volume":"2","author":"Patorno","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ebr.2025.100746_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008365","article-title":"Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study","volume":"5","author":"Renoux","year":"2015","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.ebr.2025.100746_b0170","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/epi.16930","article-title":"Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events","volume":"62","author":"Lee-Lane","year":"2021","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.ebr.2025.100746_b0175","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaneurol.2021.3424","article-title":"Association of enzyme-inducing antiseizure drug use with long-term cardiovascular disease","volume":"78","author":"Josephson","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebr.2025.100746_b0180","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/epi.17922","article-title":"Association of antiseizure medications and adverse cardiovascular events: a global health federated network analysis","volume":"65","author":"Mayer","year":"2024","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/15357597231213248","article-title":"Epilepsy and anti-seizure medications: secret agents for endocrine disruption","volume":"24","author":"Sazgar","year":"2024","journal-title":"Epilepsy Currents"},{"issue":"4","key":"10.1016\/j.ebr.2025.100746_b0190","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0537","article-title":"Menopause-associated risk of cardiovascular disease","volume":"11","author":"Anagnostis","year":"2022","journal-title":"Endocrine Connections"},{"issue":"24","key":"10.1016\/j.ebr.2025.100746_b0195","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCULATIONAHA.123.065827","article-title":"Polycystic ovary syndrome fuels cardiovascular inflammation and aggravates ischemic cardiac injury","volume":"148","author":"Gao","year":"2023","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ebr.2025.100746_b0200","first-page":"S81","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Tolou-Ghamari","year":"2013","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.ebr.2025.100746_b0205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.toxlet.2020.08.006","article-title":"Carbamazepine induces a bioenergetics disruption to microvascular endothelial cells from the blood-brain barrier","volume":"333","author":"Alelwani","year":"2020","journal-title":"Toxicol Lett"},{"issue":"9","key":"10.1016\/j.ebr.2025.100746_b0210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.seizure.2014.05.011","article-title":"The effects of antiepileptic drugs on vascular risk factors: a narrative review","volume":"23","author":"Katsiki","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100746_b0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.seizure.2019.01.014","article-title":"Co-medication and potential drug interactions among patients with epilepsy","volume":"66","author":"Bosak","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100746_b0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yebeh.2017.05.022","article-title":"Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy","volume":"73","author":"Bruun","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"12","key":"10.1016\/j.ebr.2025.100746_b0225","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/epi.16745","article-title":"Effects of lacosamide and carbamazepine on lipids in a randomized trial","volume":"61","author":"Mintzer","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.ebr.2025.100746_b0230","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2011.03118.x","article-title":"Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"52","author":"Bullman","year":"2011","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.ebr.2025.100746_b0235","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2010.07.021","article-title":"The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy","volume":"91","author":"Candrilli","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100746_b0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","article-title":"Cardiovascular consequences of metabolic syndrome","volume":"183","author":"Tune","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.ebr.2025.100746_b0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2018.06.003","article-title":"Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid","volume":"60","author":"Nisha","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100746_b0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2016.03.008","article-title":"Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine","volume":"38","author":"Rakitin","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100746_b0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2016.03.002","article-title":"Metabolic syndrome in young adults with epilepsy","volume":"37","author":"Nair","year":"2016","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.ebr.2025.100746_b0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00415-015-7967-1","article-title":"Cardiovascular adverse effects of phenytoin","volume":"263","author":"Guldiken","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.ebr.2025.100746_b0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: a pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure: Eur J Epilepsy"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1476-5381.2011.01415.x","article-title":"On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex","volume":"164","author":"Harmer","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.ebr.2025.100746_b0275","doi-asserted-by":"crossref","first-page":"76","DOI":"10.15420\/aer.2014.3.2.76","article-title":"Short QT syndrome \u2013 review of diagnosis and treatment","volume":"3","author":"Rudic","year":"2014","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"1","key":"10.1016\/j.ebr.2025.100746_b0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/epi4.12475","article-title":"FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE\/AES Task Force","volume":"6","author":"French","year":"2021","journal-title":"Epilepsia Open"},{"issue":"9","key":"10.1016\/j.ebr.2025.100746_b0285","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/epi.17339","article-title":"Cardiac morbidity and mortality associated with the use of lamotrigine","volume":"63","author":"Christensen","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ebr.2025.100746_b0290","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eplepsyres.2003.10.012","article-title":"Carbamazepine affects autonomic cardiac control in patients with newly diagnosed epilepsy","volume":"57","author":"Persson","year":"2003","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.ebr.2025.100746_b0295","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s10072-023-06871-0","article-title":"Is anti-seizure medication the culprit of SUDEP?","volume":"44","author":"Leosuthamas","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ebr.2025.100746_b0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.seizure.2021.08.003","article-title":"Exploring factors associated with interictal heart rate variability in patients with medically controlled focal epilepsy","volume":"92","author":"Yeh","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100746_b0305","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.seizure.2022.04.013","article-title":"Perampanel enhances the cardiovagal tone and heart rate variability (HRV) in patients with drug-resistant temporal lobe epilepsy","volume":"99","author":"Dono","year":"2022","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:17:39Z","timestamp":1751977059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986425000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"alternative-id":["S2589986425000061"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100746","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiseizure medications and their differing effects on cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100746"}}